Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended | |||
| Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Active | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active | |||
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| Jemperli | dostarlimab | Endometrial cancer | Active | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
| Bimzelx | bimekizumab | Psoriatic arthritis | Active | |||
| TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Received |
Last Updated : April 18, 2024